Stockwinners Market Radar for January 11, 2023 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:15 EST Nvidia director sells $33.3M in common stock - In a regulatory filing, Nvidia disclosed that its director Mark Stevens sold 210K shares of common stock on January 9th in a total transaction size of $33.3M.

20:04 EST Cathie Wood's ARK Investment bought 74.8K shares of Coinbase today

20:02 EST Oramed's results from phase 3 trial of ORMD-0801 did not meet primary endpoint - Oramed Pharmaceuticals "announced top-line results from its Phase 3 randomized, double-blind, placebo-controlled, multicenter clinical trial comparing the efficacy of ORMD-0801 to placebo in patients with Type 2 Diabetes at 26 weeks. ORA-D-013-1 enrolled 710 patients with T2D and inadequate glycemic control on two or three oral glucose-lowering agents. The ORA-D-013-1 trial did not meet its primary endpoint, which compared the efficacy of ORMD-0801 to placebo in improving glycemic control as assessed by the mean change from baseline in A1C at 26 weeks. The trial also did not meet its secondary endpoint, which assessed the mean change from baseline in fasting plasma glucose at 26 weeks. There were no serious drug-related adverse events. Therefore, Oramed expects to discontinue its oral insulin clinical activities for T2D."

18:38 EST Robinhood exec sells $905K in common stock - In a regulatory filing, Robinhood disclosed that its Chief Creative Officer Baiju Bhatt sold 106K shares of common stock on January 9th in a total transaction size of $905K.

18:22 EST Hecla Mining sees FY22 silver production 14.2M oz, up 10% y/y - Hecla Mining announced its preliminary silver and gold production for the fourth quarter and full year 2022 and certain estimates for the Keno Hill mine for 2023. Annual results: Silver production of 14.2 million ounces, Hecla's second highest, was an increase of 10% over last year driven by a 24% increase at Lucky Friday and a 5% increase at Greens Creek; As expected, gold production decreased 13% to 175,807 ounces as Nevada production ended; 12% increase in lead production; zinc production unchanged from 2021, and; Keno Hill development on schedule with production planned to start in the third quarter of 2023, ramping-up to an expected 440 tons per day (tpd) by year end. Quarterly results: 3% increase in silver and 2% decrease in gold production; Lucky Friday silver production increased 14%; Casa Berardi gold production decreased 8%, and; Lead production increased 7%; zinc production unchanged.

18:05 EST Horizon Technology originates $114M in new loans in Q4 - Horizon Technology provided its portfolio update for the fourth quarter ended December 31, 2022 and an update on the lending platform of Horizon Technology Finance Management LLC, its investment adviser. During the fourth quarter of 2022, a total of $113.5M of loans funded through the Horizon Platform, including ten loans totaling $103.9M.

17:14 EST Relativity Acquisition Corp trading halted, news pending

17:02 EST Akerna sells 365 Cannabis to 365 Holdco LLC for $2.8M - Akerna announced its sale of 365 Cannabis to 365 Holdco LLC. The sale was completed pursuant to the terms and conditions of stock purchase agreement by and between Akerna and 365 Holdco entered into by the parties on January 11, 2023. Under the terms of the SPA, as consideration for the sale of all of the outstanding shares of common stock of The NAV People, Inc, Akerna received a cash payment of $500,000 and the parties agreed to terminate an earn-out payment due and payable to the principals of 365 Holdco LLC with a deemed value of $2,283,806. $100,000 of the cash payment is being held back by 365 Holdco in accordance with the terms of the SPA for post-closing accounts payable adjustments and certain indemnification claims through April 30, 2023.

16:59 EST Scorpio Tankers announces purchase of shares in open market - The company purchased 250,217 of its common shares in the open market at an average price of $49.97 per share as part of the company's securities repurchase program.

16:36 EST Lifecore discloses Nasdaq listing compliance notice - Lifecore "announced that it received a notice on January 11, 2023 from the Listing Qualifications Department of The Nasdaq Stock Market stating that the Company is not in compliance with Nasdaq Listing Rule 5250(c)(1) because the Company failed to timely file its Quarterly Report on Form 10-Q for the quarter ended November 27, 2022 with the Securities and Exchange Commission. The Company continues to work diligently to complete the fiscal second quarter Form 10-Q and plans to file the 10-Q as promptly as possible to regain compliance with the Listing Rule."

16:34 EST Financial Strategies Acquisition extends business combination termination date - Financial Strategies Acquisition has approved an extension of the period of time available to the company to consummate an initial business combination by one month from January 14 to February 14. The purpose of the extension is to provide additional time for the company to complete an initial business combination. In connection with the extension, Temmelig Investor, an affiliate of the company's co-sponsors, has deposited $50K, representing approximately $0.081 per unredeemed share of Class A common stock issued in the company's IPO, into the trust account established in connection with the company's IPO pursuant to the company's second drawdown upon an unsecured promissory note in the aggregate principal amount of $600K issued by the company to the lender on December 9, 2022. The promissory note bears no interest and is convertible at the option of the lender upon the consummation of an initial business combination into private units of the company identical to the private placement units issued at the time of the company's IPO at a conversion price of $10.00 per private unit. The Board may elect to further extend the Termination Date on a monthly basis until December 14, 2023 upon the deposit of an additional $50K into the trust account per monthly extension.

16:32 EST UMH Properties increases quarterly dividend 2.5% - The board of UMH Properties announced that its board approved a 2.5% increase in the company's quarterly common stock dividend, raising it to 20.5c per share from 20c per share. The dividend is payable March 15 to shareholders of record at the close of business on February 15. This represents an annual dividend rate of 82c per share.

16:32 EST Victory Capital reports December AUM of $153.0B vs. $161.5B m/m - Victory Capital reported assets under management of $153.0 billion as of December 31, 2022, and average assets under management for the fourth quarter period of $154.6 billion. The Company also reported long-term net flows in the fourth quarter were -$4.4 billion, resulting in year-to-date long-term net flows of -$2.5 billion.

16:31 EST Sachem Capital announces retirement of Chief Investment Officer William Haydon - Sachem Capital announced that William Haydon, has resigned to pursue retirement and other opportunities. Haydon's responsibilities as Chief Investment Officer will be assumed by CEO John Villano. Haydon's other responsibilities will be assumed by the finance and accounting team. To ensure an orderly transition, Haydon has agreed to remain as an advisor to the company until July 31, 2023.

16:21 EST Artisan Partners preliminary AUM as of December 31 $127.9B - Artisan Partners Asset Management reported that its preliminary assets under management as of December 31 totaled $127.9B. Artisan Funds and Artisan Global Funds accounted for $60.8B of total firm AUM, while separate accounts and other AUM accounted for $67.1B.

16:18 EST Crestwood Equity sees Q4 be impacted by weather, sees FY22 below prior outlook - Crestwood Equity Partners "announced that it expects Q4 financial results to be impacted by extreme winter weather events that adversely impacted volumes and well connect activity across Crestwood's gathering & processing assets during the quarter. The severity and duration of these weather events forced producers to contend with surface equipment freezing, widespread power outages, and limited road accessibility, which resulted in well shut-ins, facility downtime, and delays in drilling and completion activity. Compared with previous expectations underpinning prior full-year 2022 guidance, Crestwood estimates fourth quarter Williston Basin gathering volumes to have decreased by approximately 15%, and Powder River Basin and Delaware Basin gas gathering volumes to have decreased by approximately 5% to 10%. As a result, Crestwood anticipates that its full-year 2022 financial results will be slightly below previously provided guidance ranges. Crestwood and its producer customers have fully resumed normal operations and expect these volume disruptions to be isolated to the fourth quarter."

16:17 EST Angi Inc. reports December revenue up 6% from last month - As previously communicated, December 2022 will be the last month we release monthly metrics, and we will return to our normal cadence of quarterly disclosure in Q1 2023. 2022 Monthly Year-over-Year Growth Trends through December

16:16 EST KB Home falls 5% to $34.20 after Q4 earnings miss and guidance

16:16 EST KB Home sees 2023 housing revenue at $5.0B-$6.0B vs. $6.88B in 2022 - Due to significant uncertainty and limited forward visibility regarding 2023 housing market, macroeconomic and geopolitical conditions, which are anticipated to be challenging compared to prior periods, the Company is providing guidance as to the full fiscal year only for the following: Housing revenues in the range of $5.00B to $6.00B.

16:15 EST IAC December Angi Inc. total revenue up 6% from last year - As part of its December monthly metrics disclosure, IAC also reports Dotdash Meredith total pro-forma revenue down 28%, and its Search business revenue down 43% from last year. Emerging & Other revenue was down 47% from last year. Reference Link

16:14 EST KB Home reports Q4 gross orders down 47% - The company states: "Reflecting sharply lower demand stemming from higher mortgage interest rates, inflation and other macroeconomic and geopolitical concerns, fourth quarter net orders of 692 and net order value of $362.7 million decreased from 3,529 and $1.77 billion, respectively. Gross orders for the quarter of 2,169 were down 47% from 4,072. The cancellation rate as a percentage of gross orders was 68%, compared to 13%."

16:12 EST Disney board does not endorse Trian Group nominee - Trian Partners L.P. and Trian Partners Parallel Fund I, L.P., wholly owned subsidiaries of Trian Fund Management, L.P., along with other entities affiliated with Nelson Peltz, have nominated Nelson Peltz for election as director at the Annual Meeting in opposition to the nominees recommended by the Board, and brought a proposal to amend Disney's Bylaws. "The Walt Disney Company remains open to constructive engagement and ideas that help drive shareholder value," Disney said. "While senior leadership of The Walt Disney Company and its Board of Directors have engaged with Mr. Peltz numerous times over the last few months, the Board does not endorse the Trian Group nominee, and recommends that shareholders not support its nominee, and instead vote FOR all the Company's nominees. The Walt Disney Company has had a long-term track record of financial and creative success, built on the ability to leverage its rich intellectual property and unparalleled storytelling across its many businesses, from theatrical, streaming and linear broadcast to parks and resorts, and one of the most resonant names in sports, ESPN. Mr. Iger's mandate is to use his two-year term and depth of experience in the industry to adapt the business model for the shifting media landscape, rebalancing investment with revenue opportunity while bringing a renewed focus on the creative talent that has made The Walt Disney Company the envy of the industry. Mr. Iger has already taken decisive steps to realign content creation and distribution, and reposition Disney's streaming platforms and linear broadcast and cable networks for enhanced profitability for the Company. Under Mr. Iger's first tenure as CEO from September 2005 through February 2020, the Company's total shareholder return was 554%, which exceeded the S&P 500 total shareholder return of 244%. The company's market capitalization grew nearly fivefold during his tenure from $48 billion to over $230 billion. The Board of The Walt Disney Company has been continually refreshed, with a focus on directors whose industry experience is additive to the company's strategic priorities. The average tenure of the current Board is four years, with three directors serving fewer than two years, and in addition the Board is led by an independent chairman."

16:12 EST AMD CFO Devinder Kumar to retire, Jean Hu appointed new CFO - AMD (AMD) announced that CFO and treasurer Devinder Kumar will be retiring from the company and that Jean Hu will join on January 23 as executive VP and CFO. Kumar will remain at AMD through April 2023 to ensure a smooth transition. Hu joins AMD from Marvell (MRVL), where she served as CFO since 2016 and was responsible for all aspects of financial planning, accounting, reporting, treasury, tax and investor relations.

16:11 EST Disney names Mark Parker chairman of the board - The Walt Disney Company Board of Directors announced that it has elected independent director Mark G. Parker as Chairman of the Board, effective following the Annual Meeting of Shareholders. Mr. Parker, a seven-year member of the Disney Board and Executive Chairman of NIKE, Inc., will succeed Susan E. Arnold, who will not stand for re-election pursuant to the 15-year term limit under Disney's Board Tenure Policy. As a result, the size of the Board will be reduced to 11 members. "Mark Parker is an incredibly well-respected leader who over seven years as a Disney director has helped the Company effectively navigate through a time of unprecedented change," Ms. Arnold said. "During his four decades at NIKE, Mark has led one of the world's most recognized consumer brands through various market evolutions and a successful CEO transition, and he is uniquely positioned to chair the Disney Board during this period of transformation." Parker will also chair a newly created Succession Planning Committee of the Board, which will advise the Board on CEO succession planning, including review of internal and external candidates. Mr. Parker served as NIKE's Chairman and CEO until 2020, when he became Executive Chairman.

16:08 EST Yield10 signs MOU with Mitsubishi to market Camelina as biofuel feedstock oil - Yield10 Bioscience (YTEN) announced that it has signed with Mitsubishi Corporation, a Memorandum of Understanding, to evaluate the establishment of a partnership to supply, offtake and market Camelina as a low-carbon feedstock oil for biofuels. Mitsubishi Corporation recently announced its aim to mass produce sustainable aviation fuel to decarbonize commercial aviation. Under the MOU, the companies plan to jointly undertake a feasibility study for the supply and offtake of Camelina oil from Camelina grain grown under contract using Yield10's proprietary Camelina seed genetics to supply oil for the sustainable aviation fuel market. In addition, the companies also plan to jointly study the development and future offtake and marketing of PHA bioplastic produced in Camelina by Yield10 as an added value co-product with oil for biofuels. The MOU is non-binding and expires at the end of 2023. e

16:06 EST Super Group board approves $25M buyback program - Super Group, the parent company of Betway, announced that its Board of Directors has authorized the repurchase of up to $25M of Super Group ordinary shares through December 31, 2023.

16:02 EST Latch names Jason Keyes as interim CEO, Marc Landy as interim CFO - Latch announced that its Board of Directors has appointed Jason Keyes as interim Chief Executive Officer and Marc Landy as interim Chief Financial Officer. These appointments are effective immediately. Latch also announced the resignations of Luke Schoenfelder as the Company's Chief Executive Officer and Chairman of the Board, as well as interim Chief Financial Officer Barry Schaeffer and Chief Accounting Officer Junji Nakamura. Mr. Schoenfelder said, "From co-founding Latch at my kitchen table to leading it to its current scale, I am enormously proud of the products we've delivered for customers, and I am excited to continue to support Latch's new leadership team as a proud stockholder and advisor going forward."

16:00 EST Scilex Holding Co trading resumes

15:14 EST Univar up 3% after Bloomberg report on PE bidder interest

14:08 EST Calix sinks 17% after presentation at Needham conference - Shares of Calix (CALX) are moving lower following the company's presentation this morning at the Needham Growth Conference. Calix CFO Cory Sindelar discussed the "difficult" supply chain lasting for most of 2023. The stock is down 17% to $57.81 in afternoon trading while broadband peer Clearfield (CLFD) is down 11% to $84.12.

14:00 EST Calix sinks 17% after presentation at Needham conference - Shares of Calix are moving lower following the company's presentation this morning at the Needham Growth Conference. Calix CFO Michael Weening discussed the "difficult" supply chain lasting for most of 2023. The stock is down 17% to $57.81 in afternoon trading while broadband peer Clearfield (CLFD) is down 11% to $84.12.

13:35 EST Neonode up 34% after USPTO ruling in patent fight with Google

13:29 EST USPTO rules Google has not shown Neonode '879 claims unpatentable - A ruling posted to the site of the U.S. Patent and Trademark Office from the Patent Trial and Appeal Board stated in part: "Petitioner Google LLC (GOOGL) filed a Petition for inter partes review of claims 1-7, 9, 12, 13, and 15-17 of U.S. Patent No. 8,095,879 [held by Neonode (NEON)] ... We held an oral hearing on October 17, 2022, and the transcript is entered on the record... This is a final written decision under 35 U.S.C. Section 318(a) as to whether the claims challenged in the inter partesreview are unpatentable. For the reasons below, we conclude that Google has not shown that any claims of the '879 patent are unpatentable." Reference Link

13:27 EST Celularity, CH Trading Group enter product distribution deal with Tamer Group - Celularity and CH Trading Grou entered into an exclusive distribution agreement with the Tamer Group. The Tamer Group will be the exclusive distributor for Celularity's branded regenerative biomaterial products in Saudi Arabia, Through the agreement, CH Trading Group will distribute to more than 100 countries that are members of or associated with the following intergovernmental organizations: The Organization of Islamic Cooperation, which has 57 member countries on four continents; The Gulf Cooperation Council, comprised of Bahrain, Kuwait, Oman, Qatar, Saudi Arabia, and the United Arab Emirates; and The African Union, which has 55 member countries. It is anticipated that these biomaterial products are to become available in Saudi Arabia in 2023 following receipt of approval from the Saudi Food and Drug Authority. Tamer is expected to be Celularity's and CH Group's local strategic partner for Celularity's Lifebank business model for placenta and cord blood banking, as well as for a new Serum Banking business and other potential research and development collaborations.

13:21 EST North American rail traffic down 2.1% for the week ending January 7 - The Association of American Railroads, AAR, reported U.S. rail traffic for the week ending January 7. For this week, total U.S. weekly rail traffic was 416,489 carloads and intermodal units, down 5.5% compared with the same week last year. Total carloads for the week ending January 7 were 212,962 carloads, up 1.4% compared with the same week in 2022, while U.S. weekly intermodal volume was 203,527 containers and trailers, down 11.8% compared to 2022. Seven of the 10 carload commodity groups posted an increase compared with the same week in 2022. They included coal, up 8,870 carloads, to 63,928; petroleum and petroleum products, up 1,215 carloads, to 10,119; and motor vehicles and parts, up 960 carloads, to 11,752. Commodity groups that posted decreases compared with the same week in 2022 were chemicals, down 7,016 carloads, to 27,356; miscellaneous carloads, down 1,691 carloads, to 7,016; and forest products, down 1,117 carloads, to 8,574. North American rail volume for the week ending January 7, on 12 reporting U.S., Canadian and Mexican railroads totaled 305,444 carloads, up 5.4% compared with the same week last year, and 271,276 intermodal units, down 9.4% compared with last year. Total combined weekly rail traffic in North America was 576,720 carloads and intermodal units, down 2.1%. North American rail volume for the first week of 2023 was 576,720 carloads and intermodal units, down 2.1%t compared with 2022. Publicly traded companies in the space include CSX (CSX), Canadian National (CNI), Canadian Pacific (CP), Kansas City Southern (KSU), Norfolk Southern (NSC),Union Pacific (UNP), Greenbrier (GBX),Trinity Industries (TRN), FreightCar America (RAIL) and Wabtec (WAB). Reference Link

12:48 EST Universal Parks announces plans for family-focused theme park in Texas - Universal Parks & Resorts announced plans for "a one-of-a-kind theme park, unlike any other in the world, specifically designed to inspire fun for families with young children." The unit of NBCUniversal, a subsidiary of Comcast (CMCSA), stated: "The proposed park will be designed to be more intimate and engaging for younger audiences and will be sized for a regional audience. It will be full of family-friendly attractions, interactive and playful shows, character meet and greets, unique merchandise and fun food and beverage venues. Although smaller in size, it will still carry the same quality as Universal's other larger resort destinations. Part of 97 acres of land recently purchased by the company, the proposed park also has plans for an adjacent themed hotel and room for expansion. The entire area is intended to have a completely different look, feel, and scale than Universal's existing parks and will appeal to a new audience for the brand. Universal Parks & Resorts selected the city of Frisco, in North Texas, as the area for this new concept given the city's growing population and ability to attract businesses to the area... More details about the project will be revealed over time." Universal competes in the theme park space with Disney (DIS), Six Flags (SIX), Cedar Fair (FUN) and SeaWorld (SEA). Reference Link

12:13 EST Ubisoft unveils revenue growth measures, cancels three unannounced projects - Ubisoft said that the currently challenging environment and disappointing sales results has triggered a full review of its revenue prospects leading to increased cautiousness over the coming years. Considering this, combined with the significant additional investments that resulted from lockdown and new working patterns that have had a profound impact on productions across the industry over the past 3 years, Ubisoft is announcing a set of measures dedicated to strengthening its long-term growth and value-creation prospects: Ensure all energy is focused on building its brands and live services into some of the most powerful within the industry. As a consequence, the company has decided to cancel three unannounced projects, on top of the four already announced in July 2022. The company also intends to depreciate around EUR500M of capitalized R&D, concerning upcoming premium and Free-to-Play games and the newly cancelled titles. This notably reflects the increased cautiousness related to the current challenging videogame market and macroeconomic environment as well as the necessary increased focus on fewer titles. As part of the company's increased strategic focus, Ubisoft seeks to adapt its organization to a more challenging market, with an expected net reduction of non-variable costs base of more than EUR200M over the next 2 years. This will be achieved through targeted restructuring, divesting some non-core assets and usual natural attrition. Ubisoft said it will continue to look at hiring highly talented people for its biggest brands and live services.

12:00 EST Debt Resolve falls -7.6% - Debt Resolve is down -7.6%, or -$3.75 to $45.55.

12:00 EST Gatos Silver rises 12.7% - Gatos Silver is up 12.7%, or 56c to $4.98.

12:00 EST Carvana rises 26.9% - Carvana is up 26.9%, or $1.19 to $5.61.

11:48 EST BASF breaks ground on MDI capacity expansion project at Geismar site - BASF has broken ground on the third and final phase of the methylene diphenyl diisocyanate expansion project at its Verbund site in Geismar, Louisiana, announced in July 2022. The company will increase production capacity to approximately 600,000 metric tons per year by the middle of the decade to support the ongoing growth of its North American MDI customers. The investment for this final expansion phase, which takes place from 2022 to 2025, amounts to $780 million. Including the first and second phases, the investment volume totals around $1 billion, making the MDI expansion project BASF's largest wholly owned investment in North America.

11:34 EST Essential Utilities' Aqua Ohio agrees to purchase URS system for $25.5M - Essential Utilities announced that its regulated water subsidiary, Aqua Ohio has signed an asset purchase agreement with Ohio's Lawrence County Commissioners to purchase the Union Rome Sewer system which includes a wastewater collection network and treatment plant serving 5,300 connections in the southeast corner of the County for $25.5M. Aqua will play a key role in improving the system's operations, which have been impacted by increasingly stringent regulatory requirements along with rising supply and material costs. In addition, Aqua's business model enables the company to offer many of the benefits of larger organizations, such as staff engineers, a dedicated customer service team and customer assistance programs.Key elements of the agreement include: Aqua will pay Lawrence County $25.5M for the assets which will be used to retire debt relating to the system and other purposes, Aqua will invest an estimated $12.7M in the wastewater system over the next five years to meet regulatory and environmental demands, All URS employees will be offered employment at Aqua after passing customary background and drug screenings. Closing of the sale is anticipated during the summer of 2023 upon approval by the Public Utilities Commission of Ohio.

11:16 EST Remark Holdings announces signed deal with Premier League soccer - Remark Holdings on Twitter announced its initial break into soccer with a signed deal with a Premier League team using RemarkAI for both security and retail. The company said: "Owner also owns #NFL team so will be great opportunity for us to cross- sell." Reference Link

11:02 EST RFK Racing enters team-wide partnership with Esperion - RFK Racing has announced that Esperion has partnered with the team for a multi-year agreement pursuant to which Esperion will promote two cholesterol lowering treatments, NEXLIZET and NEXLETOL, NEXLIZET will be featured on Keselowski's No. 6 Ford at this year's Daytona Speedweeks, including the famed Daytona 500 on February 19. NEXLETOL will be featured throughout the season on Chris Buescher's No. 17 Ford. Headquartered in Ann Arbor, Michigan, Esperion discovers, develops, and commercializes innovative medicines and combinations to lower cholesterol, especially for patients whose needs aren't being met by current treatment options.

10:05 EST Roundtable, Cinedigm, GoPro collaborate to develop GoPro Channel - Roundtable Entertainment and Cinedigm (CIDM) announced a collaboration with GoPro, Inc. (GPRO) to develop the GoPro Channel, with plans to premiere this year. The GoPro Channel joins Roundtable partner Cinedigm's extensive portfolio of over 30 streaming channels, which span several popular content genres dedicated to serving enthusiastic fan bases. The GoPro channel will feature original programming curated from GoPro's extensive library of mind-blowing sports and lifestyle videos, including both professionally produced and award-winning user-generated content, as well as new series produced from GoPro content by Roundtable.

10:03 EST Apple introduces 'Apple Business Connect,' free tool for businesses - Apple announced that it has introduced "Apple Business Connect," which the company identifies as "a free tool that allows businesses of all sizes to claim their location place cards and customize the way key information appears to more than a billion Apple users across Apple Maps, Messages, Wallet, Siri, and other apps." Eddy Cue, Apple's senior vice president of Services, said: "We created Business Connect to provide Apple users around the world with the most accurate information for places to eat, shop, travel, and more. Apple Business Connect gives every business owner the tools they need to connect with customers more directly, and take more control over the way billions of people see and engage with their products and services every day." Reference Link

10:01 EST BAE Systems awarded $12M contract from Force Research Laboratory - BAE Systems has received a $12M Phase 2 contract from the Air Force Research Laboratory to further develop a low cost, all-weather, multi-mode open architecture seeker under the Maritime Weapon Innovation Program Joint Capability Technology Demonstration. Under the terms of the contract, BAE Systems is leading the development, integration and testing of its multi-mode seeker for maritime strike applications. The company's solution extends and uses its experience from Phase 1, its precision munitions portfolio, and sensor research area.

10:00 EST Dell Technologies falls -6.2% - Dell Technologies is down -6.2%, or -$2.62 to $39.87.

10:00 EST JinkoSolar rises 9.0% - JinkoSolar is up 9.0%, or $4.82 to $58.20.

10:00 EST Carvana rises 14.3% - Carvana is up 14.3%, or 63c to $5.05.

09:47 EST Biora Therapeutics trading halted, volatility trading pause

09:47 EST Stem falls -6.0% - Stem is down -6.0%, or -53c to $8.42.

09:47 EST JinkoSolar rises 5.3% - JinkoSolar is up 5.3%, or $2.85 to $56.23.

09:47 EST AMTD Digital rises 10.7% - AMTD Digital is up 10.7%, or $1.43 to $14.90.

09:32 EST Genius Brands consolidates consumer platforms under Genuis Networks unit - As Genius Brands International continues to build its network of digital entertainment platforms, the company announced the creation of Genius Networks, consolidating Kartoon Channel!, Frederator Network, and Ameba TV under the new banner. Concurrently, Genius Brands has promoted Todd Steinman to spearhead the newly created business unit as President, Genius Networks. Steinman joined Genius Brands last year as Chief Revenue & Marketing Officer for Kartoon Channel!.

09:24 EST Maris-Tech announces development launch of Uranus-AI - Maris-Tech announced the development launch of the Uranus-AI, an up to 8K Ultra-HD video platform supporting multiple HD/Ultra-HD streams with dual Hailo's Hailo-8 AI accelerators of up to 26 tera operations per second each. The Uranus-AI, the next generation of the successful Jupiter-AI, will significantly scale-up the "Maris Edge" to support future advanced applications with ultimate performance. The Company expects to launch and introduce the Uranus-AI to the market during the fourth quarter of 2023.

09:23 EST Pokemoto opens first Texas location In Highland Village, Texas - Pokemoto, Muscle Maker expanding Hawaiian poke bowl restaurant concept announced that it will officially open its doors in Highland Village tomorrow, January 12th with a grand opening celebration on January 13th. The Highland Village opening celebration represents the first Pokemoto opening in the Lone Star state and the company's first opening in 2023. Entering the state of Texas marks Pokemoto's sixteenth state on the map for open or coming soon locations. The new Pokemoto will open its doors for a Community VIP day on Thursday, January 12th from 4:30 PM - 7:30 PM offering 50% off regular size bowls to those who serve the community. The offer is available to fire, police, EMT and medical personnel, teachers and public works employees. The doors open to the public at 11 AM on Friday, January 13th for the official grand opening where the local Pokemoto team will have samples available and a prize wheel where guests can win various prizes and coupons.

09:13 EST Goosehead Insurance announces strategic partnership with NAMB - Goosehead Insurance announces a new partnership with the National Association of Mortgage Brokers or NAMB. As the official partner of NAMB, mortgage originators, brokers and lenders nationwide will now be able to provide their clients with a fast, easy and transparent way to shop for home insurance. "Shopping for insurance can be difficult, and today's mortgage professionals need an easier, faster and more accurate way to support their clients to ensure they have the proper coverage to protect their home," said Justin Ricketts, Executive Vice President, Technology and Partnerships at Goosehead Insurance. "From Goosehead's longstanding support of the real estate and mortgage community, to NAMB's commitment to providing smart tools, technology and expert advice, this partnership is a natural fit, aligning with both organizations' values."

09:12 EST Verizon Business announces suite of digital engagement capabilities for VCC - Verizon Business announced a new suite of digital engagement capabilities for the Verizon Virtual Contact Center to enhance the end-to-end digital customer journey from virtually anywhere and at any time. With a focus on creating smart, connected, self-service and human-assisted interactions throughout the entire customer journey, the latest VCC digital solutions were designed to facilitate exceptional customer experiences. To reduce friction along the customer journey, VCC provides entirely new ways to digitally transform the customer experience: VCC Guide provides self-service, contextual guidance for web and mobile experiences; VCC Expert is a smart knowledge management and content optimization tool that optimizes content to shape the customer journey; VCC Enlighten XO builds smarter applications using auto-generated insights through artificial intelligence that's based on actual CX conversation data; VCC SmartAssist powered by Amelia is a smart conversational AI that can resolve customer and employee issues in a more natural way

09:11 EST Voya Financial selected as new service provider for Roman Catholic Archdiocese - Voya Financial announced that it has been selected as the new recordkeeper and service provider for the Roman Catholic Archdiocese of Boston 401(k) Retirement Savings Plan. As part of its commitment to advancing a secure financial future for all individuals, Voya will provide plan members with access to its industry-leading educational tools and resources. These include Voya's myOrangeMoney interactive and educational participant website experience and access to the company's Financial Wellness experience that can help inform, engage and encourage positive action. "We are excited to start this new relationship with the Archdiocese of Boston as the new recordkeeper for their 401(k) retirement savings plan," said Bill Harmon, chief client officer for Voya Financial. "At Voya, we are committed to offering a great level of service and support for our customers. As a result, our teams are fully committed to working together to help the participants of the Archdiocese of Boston's plan prepare for greater outcomes in their future."

09:08 EST Mayfair Gold closes second tranche of financing - Mayfair Gold announced the closing of the second and final tranche of its previously announced non-brokered private placement financing for proceeds of $3,450,000. The funds will be used to further the Company's successful exploration program at the Fenn-Gib gold project in the Timmins region of Ontario, for metallurgical and engineering studies, and for general working capital. The Company issued 3,000,000 common shares at a price per share of $1.15. The common shares issued are subject to a four month hold period expiring on May 11, 2023. The Company completed the first tranche of the Offering on December 19, 2022, for proceeds of $4,980,000. The aggregate proceeds from the first and second tranches of the financing is $8,430,000.

09:05 EST Synchrony reestablishes partnership with Bassett Furniture - Synchrony (SYF) announced that they are reestablishing a partnership with Bassett Furniture Industries (BSET) to launch a multi-year financing program. The program provides consumers with payment options that they can use to access promotional financing at any of the company's 92 company- and licensee-owned stores. Bassett's financing program features several Synchrony technology solutions that enhance the customer experience by streamlining and simplifying the financing application process, including prequalification, Direct to Device, and dApply. Synchrony will also regularly share advanced data analytics with Bassett. Receiving insights on valuable customer data like their financing, shopping, and servicing preferences will help Bassett improve the customer experience and drive loyalty and growth. The Bassett program will launch as part of Synchrony's HOME Network which provides a network of over five million customers across thousands of store locations nationwide. As a HOME Network partner, Bassett will have access to exclusive marketing channels and campaigns that enable them to reach those customers.

09:05 EST Fat Brands announces development deal for Fazoli's in Puerto Rico - FAT Brands announces a new development agreement in partnership with franchisee Jorge Rodriguez Lockwood to bring five Fazoli's locations to Puerto Rico over the next six years with the first opening expected in late 2023.

09:04 EST Avalon appoints Lourdes Felix to board of directors - Avalon GloboCare announced that it has appointed Lourdes Felix to its Board of Directors. Lourdes Felix presently serves as CEO, CFO, and Director of BioCorRx.

09:02 EST Digital Brands sees FY23 revenue $45.0M-$50.0M - Digital Brands Group announces its initial 2023 revenue guidance of $45.0M-$50.0M and $2.0M-$3.0M in EBITDA due to shared services operating leverage. "Our 2023 revenue guidance includes the addition of Sundry to our brand portfolio with minimal benefit from cross merchandising and the addition of Sundry to our multi-brand website, the Bailey Shop. Additionally, we expect to achieve $2.0M to $3.0M in EBITDA due to the leverage we are experiencing from our shared services platform," said Hil Davis, CEO.

09:00 EST American Virtual Cloud Technologies trading resumes

08:52 EST Vallon Pharmaceuticals expects to close GRI Bio deal in 1Q23 - Vallon Pharmaceuticals and GRI Bio announced that David Baker, President & CEO of Vallon and Marc Hertz, CEO of GRI Bio, will present at the Virtual Investor 2023 Companies to Watch Event on Tuesday, January 17, 2023 at 1:00 PM ET. As part of the presentation, Vallon and GRI Bio will discuss their previously announced definitive agreement pursuant to which GRI Bio will merge with a wholly-owned subsidiary of Vallon in an all-stock transaction. The combined company will focus on advancing GRI Bio's innovative pipeline of NKT cell modulators for the treatment of inflammatory, fibrotic and autoimmune diseases. The transaction is expected to close in the first quarter of 2023.

08:51 EST Codorus Valley Bancorp board authorizes $5M share repurchase program - The Corporation announced that its Board approved the repurchase of up to $5 million in aggregate value of the Corporation's common stock from time to time in open market or privately negotiated transactions. The Board authorization will continue until the earlier of an aggregate of $5 million of common stock has been repurchased, December 31, 2023, or until the Stock Repurchase Program has otherwise been suspended or terminated by the Board, in its sole discretion. Shares of common stock repurchased pursuant to the 2023 Stock Repurchase Program will be held as treasury shares available for use and reissuance for corporate purposes, as and when determined by the Board including, without limitation, pursuant to the Company's Dividend Reinvestment and Stock Purchase Plan and its equity compensation program.

08:49 EST CordovaCann says Star Buds stores generated $1.22M revenue in December - CordovaCann provides an update on its Star Buds Cannabis Co. retail operations in Canada. The company said, "Star Buds Cannabis Co. achieved strong performance throughout 2022. The stores continue to benefit from strong cost controls and market share gains despite a difficult economic environment. Gross margin continues to expand and management remains focused on increasing store profitability. The Star Buds Cannabis Co. stores posted a strong month of revenues in December to close out the year. For the month the store chain generated revenues of $1.22 million with a gross margin of 26.0%. This equates to a revenue run rate of $14.7 million annually. Four of the fourteen Star Buds Cannabis Co. stores posted record monthly revenues in December."

08:46 EST Camtek receives orders for its latest Eagle model totaling $18M - Camtek announced that it received a multiple systems' order from a leading global Compound Semiconductors manufacturer totaling $18M. The order is for Camtek's latest Eagle model, equipped with cutting-edge inspection technologies and designed with advanced capabilities developed specifically for this market segment. The Eagle systems are expected to be delivered starting from the Q2 of 2023 through early 2024.

08:44 EST Jaguar Health appoints Sandra Swain to scientific advisory board - Jaguar Health announced that Sandra Swain, MD, FACP, FASCO has joined the Jaguar/Napo Scientific Advisory Board. Dr. Swain is the Associate Dean for Research Development and Professor of Medicine at the Georgetown University Medical Center and the Vice President of Genetic Medicine for MedStar Health in Washington, DC.

08:42 EST Solid Biosciences and Phlox team on therapies for rare cardiac diseases - Solid Biosciences and Phlox Therapeutics, a biotech company pioneering an approach to gene therapies to alleviate and cure cardiomyopathies announced a strategic collaboration focused on genetic cardiac diseases. The research collaboration will target a severe form of genetic dilated cardiomyopathy DCM for which there is currently a significant unmet need for effective treatments. The strategic collaboration will integrate Solid Biosciences' vector biology, manufacturing capabilities and drug development experience with Phlox's deep expertise in genetic cardiomyopathies and RNA therapeutics. The companies will collaborate to develop novel precision genetic medicines for this form of DCM. "This collaboration with Phlox Therapeutics is an exciting opportunity to work with a company that shares our commitment and innovative approach to bringing transformative therapies to patients with rare genetic diseases," said Bo Cumbo, President and Chief Executive Officer of Solid Biosciences. "Our pipeline of programs focused on neuromuscular and cardiac rare disease gives us deep insight into the diverse and complex nature of dilated cardiomyopathy. We look forward to a successful partnership with the Phlox team and executing on our joint vision to develop new therapies for patient populations for which there is high unmet medical need."

08:41 EST QReal creates immersive experience for 'Sweet Tooth' fragrance on Walmart.com - QReal (VRAR) announced the completion of a paid engagement to create an immersive experience to complement the launch of Sabrina Carpenter's real world fragrance, "Sweet Tooth" on Walmart.com (WMT).The collaborative experience including singer and actress Sabrina Carpenter, Scent Beauty, and Walmart was created as a virtual experience in Decentraland as an interactive scavenger hunt with an NFT reward and a hyperlink directing users to the Walmart.com product page to purchase the fragrance. Upon entering the experience, fans were transported to Sabrina Carpenter's candy shop designed to reflect the fragrance inspiration with a sweet shop theme.

08:38 EST Avinger announces 510(k) filing for Pantheris LV - Avinger announced the Company submitted a new 510(k) application to the U.S. Food & Drug Administration for Pantheris LV, its next-generation image-guided atherectomy system for the treatment of larger vessels, such as the SFA and popliteal arteries, where the majority of PAD procedures are performed today.

08:37 EST Ensysce CEO says 'highly focused' on execution of clinical development timeline - Ensysce Biosciences issued a letter to shareholders from CEO Dr. Lynn Kirkpatrick, which read in part, "I want to take this opportunity to thank our shareholders for their continued support in 2022. As you all know, it has been a challenging year in the market and our management team and board, as fellow equity holders, too have been impacted by the turbulence. However, our science is strong as evidenced by the positive clinical data we reported throughout 2022, and we are continuing to develop a new approach to deliver opioid pain relief that we believe will save lives. I am pleased to summarize last year's events and recap the milestones achieved. During 2022 we made important progress across all of our clinical development programs, accomplishing key milestones that further advance our two lead programs which address opioid abuse and overdose. We hosted a major symposium at a meeting of pain experts, receiving very encouraging feedback on our performance and underlying science. We are highly focused on positioning our technology platforms, TAAP and MPAR as "next generation" opioid products, providing strong efficacy with a unique goal of curbing prescription drug abuse and overdose...Looking ahead, we are highly focused on the continued execution of our clinical development timeline. We expect additional clinical data from our oral HAP study, PF614-104, to be reported in the first quarter of 2023. We will continue our development of PF614-MPARTM, with data expected in the second half of the year. We are also planning regulatory discussions with the FDA to aid our future clinical development plans, and we are aiming to bring PF614 into additional clinical studies by the year end."

08:34 EST Neogames' Pariplay partners with Resorts Digital Gaming - NeoGames announced that its subsidiary Pariplay has partnered with Resorts Digital Gaming, the online arm of Resorts Casino and Hotel, in a deal that will see the online brand take a collection of proprietary and third-party content via the Fusion platform. Resorts Digital customers will be able to enjoy a plethora of titles from Wizard Games including successful localized titles as Spirit of Mustang and Wolf Riches.

08:33 EST Heritage Global Capital reaches $100M milestone - Heritage Global Capital, a division of Heritage Global, announced that to date it has, together with its senior lenders, funded financial portfolio acquisitions of $100M. "Reaching the $100M mark is an exciting milestone for us and demonstrates our ability to leverage the opportunities we're seeing as the current economic environment continues to drive significant increases in charge-off volume. Over the years, we've developed strong client relationships as well as strategic lending partnerships, and these, coupled with the extensive experience and knowledge of our HGC management team, position us well in our goal to become a premier lender. As we celebrate this milestone, we also look forward to continuing to support our clients, and believe our achievement of the next $100M in funding is just over the horizon," commented Ross Dove, CEO of Heritage Global Inc.

08:31 EST Meihua subsidiary announces cooperation agreement with Getein Biotech - Meihua International Medical Technologies announced the Company's subsidiary Jiangsu Huadong Medical Device Industrial has entered into a strategic cooperation agreement with Getein Biotech, to jointly produce and sell Covid-19 antigen test kits and other in vitro diagnostics, or IVD, products. Under the Cooperation Agreement, Jiangsu Huadong will serve as an exclusive production, research and development center for Getein Biotech in Northern Jiangsu Province, which will initially be dedicated to the production of Covid-19 antigen test kits, with the aim of producing other high-end IVD medical device products in the future. The Company recently completed a brand-new workshop, built in accordance with good manufacturing practices, that covers an area of more than 8,000 square meters with an additional 15,000 square meters of commercial warehousing space. The production base is equipped with 52 new fully automated Covid-19 antigen test kit production lines. Jiangsu Huadong will hire an additional workforce of more than 400 workers and 35 technology staff who will safeguard production of all products. The facility has obtained Class III medical device production certification, a requirement of the Jiangsu Provincial Food and Drug Administration of China, and will be ready to commence production after January 16, 2023.

08:30 EST PharmaTher provides update on KETARX development programs - PharmaTher Holdings provided an update for its clinical development programs and milestones for 2023 with KETARX as a potential treatment for mental health, neurological and pain disorders. Racemic ketamine was approved by the U.S. Food and Drug Administration in 1970 and is clinically used for analgesia, sedation, and anesthetic induction. The Company believes it is in a unique position to unlock the commercial and therapeutic potential of KETARX in the near term by leveraging its indication-specific patents, FDA orphan drug designations, and drug delivery technologies. The aim is to obtain FDA approvals through the less burdensome abbreviated new drug application and 505(b)(2) regulatory pathways as compared to new chemical entity clinical development. KETARX Development Program Updates and Anticipated Milestones: KETARX for FDA approval via the ANDA regulatory pathway in H2-2023: PharmaTher aims to commercialize KETARX, a non-barbiturate anesthetic used for the induction and maintenance of general anesthesia for diagnostic and surgical procedures. Available dosage forms will include 10 mg/1ml, 50 mg/ml and 100 mg/ml, with the option to increase concentration and ready-to-administer applications. The Company seeks to file an ANDA with the FDA by Q2-2023 and expects to obtain FDA approval in 2023. The Company forecasts that it could sell up to one million units at an average wholesale price between USD $25 and USD $40 per unit, resulting in potential total gross sales of USD $25-40 million. KETARX for FDA approval to treat Complex Regional Pain Syndrome via the 505(b)(2) regulatory pathway in H2-2023: PharmaTher received an FDA orphan drug designation for ketamine in treating complex regional pain syndrome, a rare chronic pain and inflammatory condition. The Company recently received FDA guidance via a Type C meeting on KETARX's requirements prior to submitting a new drug application for approval in CRPS. PharmaTher believes that there is a pathway to submit an NDA with available non-clinical and clinical data, and its own chemistry, manufacturing, and controls information by the end of 2023. The Company is currently preparing its final plans, which include a robust pharmacokinetic study to potentially satisfy FDA's requirements for an NDA submission. KETARX On-body Pump for FDA approval via the 505(b)(2) regulatory pathway in H2-2023: PharmaTher aims to commercialize KETARX On-body Pump for the maintenance of general anesthesia for diagnostic and surgical procedures. The Company believes that subcutaneous infusion of racemic ketamine via the on-body pump device has several advantages for ketamine procedural sedation, including decreased requirement for skilled personnel for its administration, reduction in pain and irritation associated with administration, and a reduced risk of systemic infection and other complications seen with IV administration. The FDA is expected to grant a Type C meeting to provide feedback on the requirements to file an NDA via the 505(b)(2) regulatory pathway. PharmaTher believes there is a pathway to submit an NDA with available non-clinical and clinical data, and its own CMC information by the end of 2023. KETARX Microneedle Patch via the 505(b)(2) regulatory pathway in H2-2023: The Company recently completed the development of the microneedle patch system for the intradermal delivery of sustained low-dose ketamine. This milestone has enabled progression toward process validation and the manufacturing of cGMP clinical materials to support ongoing clinical development. PharmaTher aims to submit a pre-IND meeting with the FDA to agree on the proposed overall clinical development program via the 505(b)(2) regulatory pathway and expects to initiate a Phase 2 study in H2-2023. KETARX Type C meeting granted by FDA for potential Phase 3 clinical study in the treatment of levodopa-induced dyskinesia in Parkinson's disease patients: PharmaTher recently announced the presentation of the Phase 1/2 clinical study involving ketamine in the treatment of levodopa-induced dyskinesia in Parkinson's disease. The data from this study demonstrated ketamine's safety and tolerability with clinically meaningful efficacy that supports further investigation in a proposed Phase 3 clinical study as a potential new treatment for LID-PD. Accordingly, the Company was granted a Type C meeting with the FDA to discuss its proposed Phase 3 clinical study, which would pave the way for FDA approval under the 505(b)(2) regulatory pathway. PharmaTher retains rights to US Patent No: 11,426,366, titled "Compositions and Methods for Treating Motor Disorders," which includes claims intended to cover ketamine in the potential treatment of Parkinson's Disease and motor disorders that cause involuntary or uncontrollable movement or actions of the body. KETARX in Phase 2 clinical study in the treatment of ALS: PharmaTher received an FDA orphan drug designation for ketamine in the treatment of amyotrophic lateral sclerosis, a progressive neuromuscular disease with a life expectancy of two to six years after diagnosis. The Company announced that the FDA had accepted an investigator-initiated IND to proceed with a Phase 2 clinical study evaluating ketamine for ALS. The study's primary investigator is Dr. Richard Barohn, M.D. Currently, the Company is evaluating potential grant funding to support the initiation of the study. Upon completion of the study, PharmaTher aims to seek guidance from the FDA to determine the final clinical development plan.

08:28 EST FAA 'making progress' in restoring NOAM system following outage - The FAA said via Twitter: "The FAA is making progress in restoring its Notice to Air Missions system following an overnight outage. Departures are resuming at @EWRairport and @ATLairport due to air traffic congestion in those areas. We expect departures to resume at other airports at 9 a.m. ET." Publicly traded companies in the space include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Airlines (UAL). Reference Link

08:24 EST PCS Edventures!.COM says Iowa STEM funding available for drone education - PCS Edventures! announced that as of January 9, 2023, the Iowa Governor's STEM Advisory Council has begun accepting applications for educators to receive access to highly-vetted STEM programs, including its Discover Drones program for middle and high school students. Mike Bledsoe, President of PCS Edventures commented, "We are proud to partner with the Iowa Governor's STEM Advisory Council for a second year in a row to further their mission of increasing student interest and achievement in STEM across all demographics. We believe that our programs excel in capturing student interest and fueling their passion for STEM."

08:23 EST Cyclo Therapeutics provides clinical program update - Cyclo Therapeutics provided updates for the Company's Trappsol Cyclo clinical program and provided a summary of key achievements in 2022, focused on our clinical portfolio of two neurodegenerative diseases with major unmet medical needs. "We have continued to execute and make significant progress on our clinical programs evaluating Trappsol Cyclo for the treatment of NPC and early Alzheimer's disease. We recently announced the commencement of patient enrollment and dosing in our early AD clinical study and are dedicated to building momentum for that program. Additionally, we continue to make significant progress in our ongoing TransportNPC and remain on target to have the study completely enrolled by year end, a true testament to our team's dedication, time, and effort. The Company has and will continue to focus the majority of its resources, both human and capital, to the NPC community and on advancing the TransportNPC study, an important area with significant unmet need," commented N. Scott Fine, CEO of Cyclo Therapeutics. Trappsol Cyclo Clinical Program Update: Niemann-Pick Disease Type C1 Development Program: Continued progress in patient enrollment with 35% in the ongoing TransportNPC study completed to-date and dosing ongoing across multiple regions; Announced the publication of Phase 1 data for Trappsol Cyclo for the treatment of NPC in the official journal of the Society for Inherited Metabolic Disorders, Molecular Genetics and Metabolism; Announced the formation of Global Steering Committee comprised of leading experts to advise on the global Phase 3 clinical development program for Trappsol Cyclo in NPC. Alzheimer's Disease Development Program: The ability of Trappsol Cyclo to gain access to the CSF/brain and impact CSF tau and serum 24S-hydroxycholesterol when intravenously administered in NPC patients are very promising and represent a unique therapeutic development. Accelerated planning and start up phase for Phase 2b clinical trial. Commenced and initiated patient enrollment and dosing in its Phase 2b study of Trappsol Cyclo for the treatment of early AD, targeting the reduction of amyloid beta and tau. Accelerated planning and startup phase for Phase 2b clinical trial

08:21 EST Brainsway: Insurance coverage in Washington extends coverage in OCD treatment - BrainsWay announced that a major private insurance company in Washington state will extend positive coverage applicable to Deep Transcranial Magnetic Stimulation Deep TMS for the treatment of obsessive-compulsive disorder OCD as of February 3 . This policy extension provides coverage of Deep TMS for OCD to approximately 2.2M members. The policy change also reduces major depressive disorder MDD TMS coverage criteria from four failed medication trials to only three. OCD coverage criteria is also three failed medication trials. "Over the past two years, BrainsWay has seen significant coverage expansion of Deep TMS, including reduced patient selection criteria and earlier access to treatment for both MDD and OCD patients," said Scott Blackman, Director of Market Access of BrainsWay. "This has been especially evident in the Medicare population where all Medicare administrative contractors now cover depression with only one or two failed medication trials."

08:19 EST Genetic Technologies provides update on 2023 priorities - Genetic Technologies provides the following business update for the first half of the 2023 financial year. Te company said, "Operating in the multibillion dollar predictive and consumer genomics markets, GTG has achieved five consecutive quarters of growth. Our portfolio features the most comprehensive genetic solutions for the modern medical challenges. Our presence is building, now operating in more than 40 countries with more than 50 tests on offer via our global network of partner laboratories. Our priorities focus on the following core areas to secure further commercial growth and revenue: Business to Business commercialisation of our geneType suite of tests; Demonstrating clinical validity and utility of our priopritary geneType platform; Driving revenue growth for EasyDNA and Affinity DNA with the introduction of new tests, distribution channels and markets. 1. Business to Business commercialisation of the geneType suite of tests: The Company's geneType tests are underpinned by 27 patents, 18 of which are granted patents, protecting geneType sales in key markets...For the geneType Breast Cancer Risk Assessment Test, multiple discussions highlighting the significant health and economic benefits of implementing the GeneType test were held with U.S. employer groups, unions and health systems. This has led to positive engagement with Insurers and Payors. The BIM is is scalable for all payer systems and proven to deliver near tem ROI. Currently we are engaged in more than ten active conversations with U.S. payer groups which combined have an aggregated covered lives total an estimated 42million people. GTG are also targeting smaller niche payers such as employer groups. Commercial pilot studies highlighting the benefits of adopting the GeneType test with one or more payers are expected to commence during the coming months. Completion of these pilot studies are an important inflection point for the Company. At the clinical practice level, GTG now has a number of independent clinics regularly referring patients for geneType tests, with new clinics being added weekly. GTG has also engaged with a number of KOL's in the U.S. who are actively supporting the implementation of the geneType risk assessment tests...In Australia, through the sales efforts of our Virtual Sales Representative and face to face engagements using MedLab Medical Science Liaison personnel, over 90 medical practices are currently evaluating the geneType platform with their patients. A number of these have begun referring patients on a commercial basis...2. Demonstrate clinical validity and clinical utility of geneType platform In recent weeks, GTG has announced the publication of three separate peer-reviewed papers in scientific journals which validate the benefits of the geneType test. These papers assess geneType as a predictor of breast cancer, ovarian cancer, cardiovascular disease and type 2 diabetes. They each provide growing evidence of the clinical utility of geneType providing increased awareness amongst physicians which will assist in escalating the adoption of the geneType platform...GTG will continue the strong commitment to scientific and clinical validity with our publication strategy in peer reviewed journals with innovation for geneType focussed on ethnicity diversity for a global healthcare system. 3. EasyDNA and Affinity DNA Revenue Growth: Tests, Channels & Markets: The Company's revenue base continues to grow through the EasyDNA and Affinity brands. Commercial achievements made during the half-year include: Launching a carrier test and Non-Invasive Prenatal Tests into Europe;Partnering in India with stud farms extending our paternity infrastructure into the equine industry; Launching a DNA storage solution within our Australian based NATA approved facility; Creating a NEW EasyDNA Website and eCommerce Platform, which is expected to launch in the coming weeks Our growth strategy for EasyDNA focuses on expanding Direct-to-Consumer channels and our U.S. presence."

08:17 EST Veradigm announces new $250M share repurchase program - Veradigm announced that its Board of Directors has approved a new share repurchase program under which Veradigm may purchase up to $250M of its common stock. The new share repurchase program does not have a termination date and replaces the previous authorization to repurchase $250M of common stock which was almost fully utilized during 2022. In the fourth quarter of 2022 Veradigm repurchased $57M of its common stock, bringing its full year total to $234M.

08:14 EST AAR Corp. CEO John Holmes named Chairman of the Board - AAR CORP. announced that John M. Holmes, President and Chief Executive Officer of AAR has been named Chairman of the Board of Directors following the retirement of David P. Storch, the Company's Chairman for 18 years. Holmes will continue as President and Chief Executive Officer of the Company. Holmes joined AAR in 2001 as Director of Mergers and Acquisitions. In 2003, Holmes moved into operations, becoming General Manager of AAR's Parts Supply business and progressively assuming responsibility of other businesses before being appointed as President and Chief Operating Officer in 2017. In 2018, he was named President and Chief Executive Officer of AAR, the third since the company's founding in 1955.

08:12 EST Aprea doses 1st patient inATRN-119 trial in advanced solid tumor treatment - Aprea Therapeutics announced that the first patient was dosed in its Phase 1/2a monotherapy clinical trial of ATRN-119, the Company's lead ATR inhibitor for the treatment of cancers with DDR mutations. The Phase 1/2a clinical trial is a multi-center, open-label, dose-escalation and expansion study designed to test ATRN-119 monotherapy in patients with advanced solid tumors harboring defined mutations in DDR pathways. The Phase 1 part of the study will assess tolerability, pharmacokinetics, recommended Phase 2 dose and analysis of patient biomarkers. The Phase 2a expansion portion of the trial is designed to further evaluate tolerability and efficacy of ATRN-119 monotherapy. ATRN-119 is structurally differentiated from other ATR inhibitors. In preclinical studies, ATRN-119 has demonstrated potent anti-proliferative activity against a variety of cancer cell lines, inhibited tumor growth in genetically defined ovarian, colon, pancreatic and prostate cancer xenograft models and has shown potential to have lower hematological toxicity than other ATR inhibitors. "Initiating clinical evaluation of ATRN-119 marks a significant milestone in our efforts to advance the development of our growing pipeline of DDR inhibitors," said Oren Gilad, Ph.D., President and Chief Executive Officer of Aprea Therapeutics. "We are committed to developing and advancing next-generation, synthetic lethality-based therapies to address the unmet medical needs of patients with genetically defined cancers. We look forward to sharing the preliminary data from this study throughout 2023."

08:12 EST NextGen Healthcare's platform added by Eye Health America - NextGen Healthcare announced that Eye Health America has added NextGen Patient Experience Platform and NextGen Pay powered by InstaMed to enhance the patient experience. The decision to add these capabilities to its core NextGen Enterprise EHR and Practice Management platform is part of a concerted effort to integrate workflows to benefit patients and providers. With NextGen Patient Experience Platform and NextGen Pay, patients can make real-time appointments and online payments and gain quick access to their medical records.

08:10 EST Amstel partners with CONMEBOL Libertadores Femenina - Amstel has partnered with CONMEBOL Libertadores Femenina, South America's growing women's club football tournament. This news comes alongside the brand's announcement that it will be extending its deal as 'official sponsor' for the prestigious South American football men's club tournaments until 2026. Amstel's sponsorship announcement in support of the CONMEBOL Libertadores Femenina is helping drive the global growth and popularity for women's football shown by record breaking attendance at women's football matches around the world.

08:09 EST ClearPoint Neuro announces 2023 anticipated milestone - Business Outlook and Planned Value Creating Milestones: The Company estimates revenue in 2023 to be between $25.0 million and $27.0 million, representing growth between 22% and 31%;Submission to the FDA of a Biologics License Application by PTC Therapeutics for Upstaza, using the ClearPoint SmartFlow Cannula, for minimally invasive infusion of the gene therapy; Initiation of multiple pharmaceutical partner clinical trials globally; Expansion of the installed base to approximately 10 additional centers worldwide; Revenue growth from international customers driven by 8 active centers installed in the E.U. and U.K.; Commercialization of the ClearPoint PRISM Neuro Laser Therapy System and expansion into limited market release centers; Completion of Phase 1 safety study in Lund, Sweden, for the use of PRISM to treat brain lesions; Up to 8 FDA submissions for new hardware and software products in our portfolio; Production of first devices at our new expanded manufacturing facility in California.

08:09 EST Academy Sports to open first location in Lafayette, Indiana this spring - Academy Sports and Outdoors will open its first location in Lafayette, Indiana in the spring of 2023. The fourth location in Indiana is set to open in Lafayette Pavilions and will be over 60,000 square feet. Academy plans to continue its expansion efforts with the goal of opening a total of 80 to 100 new stores by the end of 2026. This location is expected to bring an estimated 60 new jobs to the community.

08:05 EST Entegris announces $50M expansion investment for electronic chemicals business - Entegris announced its plans to increase production and purification capacity for its Pueblo, Colorado, and Hollister, California, sites to support the anticipated increase in demand for its Electronic Chemicals business. The Electronic Chemicals business is part of Entegris' Advanced Planarization Solutions, APS, division and includes ultra-high purity acids, bases, solvents, and formulated blend chemistries for use by semiconductor manufacturers in the U.S., Europe, and SE Asia regions. These capacity investments supplement ongoing investments in Europe and Southeast Asia and are being made to support the increasing demand by advanced node customers investing in North America and Europe for low-organic solvent1 & higher-purity cleaning chemistries. "We are pleased to announce these two capacity expansion projects at existing sites in the U.S.; these will solidify the leadership position achieved by the Electronic Chemical business with key customers and position this business well for the future. The recent enactment into law of the CHIPS for America Act as well as the European Chips Act reinforce our belief that it is time to expand capacity and capability in anticipation of new customer fabs coming on stream in 2024 and 2025," said Bertrand Loy, Entegris president and CEO.

08:05 EST FactSet, Coin Metrics collaborate for digital asset data, analytics - FactSet announced its collaboration with Coin Metrics to integrate the company's leading digital assets data across FactSet's solutions. The integration of the crypto asset class empowers financial professionals to actively monitor their digital assets workflow from research to asset allocation, stay on top of the latest market trends, and fully analyze portfolios in FactSet's portfolio analytics, performance attribution, predicted risk and reporting solutions. Additionally, the collaboration adds digital assets sector coverage through FactSet's flagship StreetAccount news service. Coin Metrics synthesizes a complex mosaic of sources into hundreds of instrument-specific metrics that lead to financial intelligence. For 200 of the most institutionally relevant digital instruments, this begins with reference rates, which use a transparent and independent methodology, are robust to manipulation, and derived from high-quality constituent markets. FactSet and Coin Metrics also plan to collaborate on new thematic indices that include a digital component and will make further announcements upon official launches.

08:03 EST Urban-Gro appoints JT Archer as Chief Operating Officer - Urban-Gro announced the appointment of JT Archer as Chief Operating Officer. "We are excited to have JT join our executive management team as COO. JT is a proven leader and skilled operator who will be instrumental in leading our team as we scale to meet demand and execute against the strong backlog we have built heading into 2023," commented Bradley Nattrass, Chairman and CEO of urban-gro. "Since joining urban-gro in February of 2022, JT has worked on framing the go-to-market strategy for our design-build offering, improving our customer experience, and driving our growing team to consistently add value to our clients' projects." Mr. Archer was previously the Company's Executive Vice President of Business Operations. Prior to joining urban-gro, Mr. Archer served in numerous operations and sales roles including most recently, as VP of Construction and Market Development for the Multi-State Operator, 4Front Ventures. Mr. Archer holds a M.S. degree in Management from the University of Colorado, Denver.

08:03 EST American Virtual Cloud Technologies trading halted, news pending

08:02 EST DiamondRock updates preliminary results for November and December 2022 - DiamondRock Hospitality provided an update on preliminary results for November and December 2022, showing continued strong revenue growth compared to 2019. November comparable revenues grew 27.3% and 7.1% compared to 2021 and 2019, respectively. December comparable revenues grew 10.5% and 10.7% compared to 2021 and 2019. Preliminary fourth quarter comparable revenues increased 23.4% and 8.5%, compared to 2021 and 2019, respectively. Preliminary full year 2022 comparable revenues increased 56.3% and 6.2%, compared to 2021 and 2019, respectively. "DiamondRock's portfolio set new records in 2022 with total owned revenue exceeding $1 billion for the first time in the company's history," stated Mark Brugger, President and CEO of the company. "We saw continued strength in travel demand during the fourth quarter with room rates meaningfully exceeding pre-pandemic levels at both our urban and resort properties."

07:39 EST StarTek enters into definitive agreement to sell interest in CCC - Startek announced that ESM Holdings Limited, an indirect wholly-owned subsidiary of the Company, has entered into a definitive share purchase agreement with Arabian Internet and Communications Services Company to divest its stake in Contact Center Company, CCC, to Solutions. The agreement is subject to customary closing conditions, third-party consents and regulatory approvals, including consents required under the Startek secured revolving credit facility and senior term loan facility agreement. Startek owns 51 percent ownership interest in CCC with the remaining 49 percent ownership interest held by STC. Pursuant to a share purchase agreement with Solutions, Startek and STC will divest their respective ownership interest in CCC at an enterprise value of SAR450 million, subject to debt-like and working capital adjustments. At prevailing exchange rates, this values the Startek stake at U.S. $61.2 million subject to closing adjustments and capital gains taxes. It is anticipated that Startek will utilize the net proceeds from the transaction to pay down amounts outstanding under its secured revolving credit facility and senior term loan facility agreement. "The journey with CCC has been highly successful and I am grateful to all the associates who have made this possible. I am confident of their continued success under the ownership of Solutions," said Bharat Rao, CEO, Startek. "The divestment of CCC will support the Startek business as we deleverage the balance sheet and prioritize growing our core business." The transaction is expected to be completed during the second quarter of 2023.

07:37 EST Cryptyde releases 2023 corporate overview presentation - Cryptyde announced that it has released its 2023 corporate presentation. This will be filed as a Current Report on Form 8-K with the U.S. Securities and Exchange Commission.

07:36 EST Osisko Development files technical report for Cariboo Gold Project - Osisko Development announces that the Company has filed a technical report, in accordance with National Instrument 43-101 - Standards of Disclosure for Mineral Projects, for the Company's 100%-owned Cariboo Gold Project, titled "Feasibility Study for the Cariboo Gold Project, District of Well, British Columbia, Canada" and dated January 10, 2023. The Technical Report was prepared and compiled for Osisko Development by independent representatives of BBA Engineering and supported by independent consulting firms, including InnovExplo, SRK Consulting, Golder Associates, WSP USA, Falkirk Environmental Consultants, Klohn Crippen Berger, KCC Geoconsulting, and JDS Energy & Mining, each of whom is a "qualified person", as reported in the Company's news release dated January 3, 2023. The Technical Report supersedes the prior technical report on the Project dated May 24, 2022.

07:34 EST KemPharm promotes Guenther to Chief Scientific Officer, Mickle to CPDO - KemPharm announced the promotions of Sven Guenther, Ph.D., to Chief Scientific Officer, and Christal M.M. Mickle, M.A., to Chief Product Development Officer. Ms. Mickle, a co-founder of KemPharm, and Dr. Guenther have been members of KemPharm's leadership team since the early days of the Company. "Christal and Sven have been integral to KemPharm's growth and success, and we look forward to benefiting from their expertise as we continue our strategic transformation into a leading rare disease company," said Richard W. Pascoe, Chief Executive Officer of KemPharm. "Key to maximizing our value will be the New Drug Application resubmission for arimoclomol to the U.S. Food and Drug Administration the ongoing development of our product portfolio, led by KP1077, and the advancement of our research and development efforts. Christal and Sven will continue to be instrumental to these endeavors, as well as continuing to provide important perspective as KemPharm embarks on a new chapter in its corporate evolution."

07:33 EST Lipella reports results from Phase 2a clinical trial of drug candidate LP-10 - Lipella Pharmaceuticals announced top line results of the Company's recently completed Phase 2a clinical trial evaluating the safety and efficacy of its drug candidate LP-10 for Hemorrhagic Cystitis, a rare but highly morbid disease for which there are currently no FDA approved treatments. Jonathan Kaufman, CEO, will present a corporate overview including the top-line results, at Biotech Showcase 2023 on Wednesday, January 11th at 2:00pm PST at the Hilton San Francisco. "The successful completion of the Phase 2a clinical trial of LP-10 is a critical milestone in Lipella's development," said Kaufman. "We're gratified with the results and look forward to our next step, which will be to communicate with the FDA on the study's results and the pathway forward to seeking regulatory approval for LP-10. The achievement of this milestone brings Lipella one step closer to providing a first-in class treatment for the cancer survivor community with hemorrhagic cystitis." The LP-10 Phase 2a clinical trial was a multi-center, dose-escalation study. The study recruited 13 subjects with moderate to severe refractory hemorrhagic cystitis. These subjects were treated with up to two courses of LP-10 intravesical bladder instillations. All subjects tolerated LP-10 instillations and completed the study without report of product related serious adverse events. LP-10 pharmacokinetic analysis demonstrated short duration of systemic uptake. A dose response was noted and there were decreased hematuria; decreased cystoscopic bleeding and ulceration sites; and improved patients' urinary symptoms.

07:21 EST Electra Battery Materials releases Sustainability Report - Electra Battery Materials released its inaugural Sustainability Report outlining the Company's progress on environmental, social, and governance, ESG, matters in 2022 and commitments to sustainable, low-carbon production of battery grade materials at its refinery complex north of Toronto. "2022 was marked by considerable progress on a number of ESG fronts," said Trent Mell, Electra's CEO. "Most notably, we launched our ESG policies and framework, appointed Renata Cardoso, an experienced sustainability expert, as VP of Sustainability and Low Carbon, became members of the Responsible Minerals Initiative, and signed a benefits agreement with the Metis Nation of Ontario. Our commitment to annual sustainability reporting will hold Electra accountable for transparent disclosure of the Company's contribution to sustainable development. We will build on these milestones as we complete the commissioning of our cobalt sulfate refinery and our black mass recycling trial program over the coming months and begin commercial production in 2023. Key to our success will be to leverage our low-carbon hydrometallurgical production facilities and establish Electra as an ESG leader within the electric vehicle battery supply chain in North America."

07:20 EST ICL signs strategic partnership agreement with General Mills - ICL (ICL) announced it will be the strategic specialty phosphate solutions supplier to General Mills. The long-term agreement will begin in June of 2023 and will initially be focused on supply in North America, with the potential for international expansion. "Our focus is always on the customer and on delivering best-in-class product, quality and service. We're pleased General Mills appreciates our efforts and is also dedicated to providing best-in-class products to their customers," said Phil Brown, president of ICL Phosphate Specialties and managing director of North America for ICL. "We're looking forward to working with their R&D team to find new ways to support their product development and are excited to turn to our global innovation team for support."

07:17 EST Idaho Strategic releases first results from Diamond Creek REE Project - Idaho Strategic Resources announces its first drill results from the Diamond Creek REE Project in Lemhi County, Idaho. Diamond Creek is a well-recognized rare earth element occurrence, which is listed as a top ten domestic source of REE's in various USGS documents. Although it has a published resource, it is based on surface sampling only and is unverified. Previous to this year's drilling only two shallow core holes were completed in 2012 with unknown results. Our objective this year was to verify the existence of REE mineralization, assess the grades and examine the extents of this potential resource. The deposits in the Diamond Creek area are of two types: fracture filling and replacement, with the replacement bodies being composed of bright and varied oxides. Much of the core drilling was in the Lucky Gem area where strong REE mineralization at surface was also encountered A rough geometry developed from drillholes 5, 6 and 7; placed drillhole DC 22-8 in position to drill down dip through the shallow dipping replacement body. The drillhole collared into a fault and encountered REE mineralization immediately after the fault, which continued for 50.3 meters before the hole was lost. DC 22-8 Rare Earth Elements highlights: 1.3% TREO over 11.3 m from 2.9 m to 14.2 m including the following higher-grade interval: 2.2% TREO over 1.1 m from 13.1m to 14.2m; 1.0% Nb over 0.5 m from 9.6 m to 10.1 m.DC 22-8 Niobium highlights: 0.7% over 10.1 m from 2.9 m to 13.0 m including the following higher-grade interval: An appealing characteristic with Diamond Creek and other properties in the Idaho Rare Earth Element-Thorium Belt is the abundance of neodymium. The company had three assays that were greater than 3000 ppm or 0.3% neodymium. In addition to the validation of REEs through the drill bit, another equally important discovery was made; the strong occurrence of Niobium. Core hole DC 22-8 showed intense enrichment of Niobium, with 0.7% Nb over 10.1m, including 10,000 ppm Nb over 0.5m.

07:13 EST Laser Photonics board authorizes stock repurchase program up to 2M shares - Laser Photonics Corporation announced that its Board of Directors authorized a share stock repurchase program permitting the Company to purchase up to an aggregate of 2 million shares of common stock.

07:13 EST Syneos Health partners with Fosun Pharma USA to launch serplulimab - Syneos Health (SYNH) announced a strategic partnership with Fosun Pharma USA (SFOSF). As part of the partnership, Syneos Health will provide Full-Service Commercial support through its Syneos One team for the launch of Serplulimab, a novel anti-PD-1 antibody for extensive stage small cell lung cancer, in the US. The therapy is a monoclonal antibody developed by Shanghai Henlius Biotec and Fosun Pharma USA has the exclusive right to commercialize Serplulimab in the US upon regulatory approval. Serplulimab has the potential to be the world's first anti-PD-1 mAb for the first-line treatment of SCLC and is the first asset as part of the partnership with Syneos Health. Over time, the partnership between the two companies is expected to expand further, continuing to leverage a product development team of experts and full commercial infrastructure within Syneos One to support Fosun Pharma USA's growth. Specifically, for Serplulimab, Syneos Health will provide Medical Affairs, Market Access, Marketing, Sales, and Operations capabilities, as well as staffing, to help Fosun bring new products to market and fill important unmet needs for patients.

07:09 EST Toyota, Lexus offer lower emissions EV charging program - Toyota Motor North America has recently entered into an agreement with WattTime to provide certain health and environmental impact data to Toyota and Lexus customers with eligible vehicles to enable them to find ideal charging times to reduce emissions when charging at home. By using this data to make more informed decisions on charging times, customers are empowered to do their part to help reduce power plant emissions that impact human health and climate change. Leveraging the power of the Remote Connect feature within the Toyota and Lexus apps, Toyota and Lexus BEV and PHEV customers will be able to manage their home charging experience, via the ECO Charging feature, to select the most efficient times to charge their vehicles.

07:07 EST Tilray's SweetWater Brewing Company announces 26th Anniversary Throwdown - SweetWater Brewing Company announces its 26th Anniversary Throwdown, an all-day party featuring throwback beers, art and musical performances by Lotus, The Floozies, Dogs in a Pile, and Hedonistas. The event will take place on Feb. 18 at the Atlanta brewery from 1 p.m. to 11 p.m. In honor of the craft beer drinkers who have supported the brewery over the years, SweetWater will be re-releasing popular seasonal and year-round beers in 2023 that customers have asked to bring out of retirement.

07:06 EST Equinox Gold reports Q4 production 150,439 ounces of gold - Equinox Gold reported that the Company recorded its strongest production quarter for the year with 150,439 ounces of gold produced in Q4 2022, for FY22 production of 532,319 ounces of gold. The Company ended the year with approximately $200M in cash. The 2022 production and cash balance figures are preliminary and subject to change when the Company releases its Q4 2022 and annual 2022 financial and operating results in late February. Greg Smith, President & CEO of Equinox Gold commented: "Q4 was our strongest production quarter in what was overall a challenging year for the Company from an operational perspective, with both inflationary cost pressures and underperformance at some of our mines. However, 2022 was also a year of substantial progress. The Greenstone team continued to advance construction of the mine on budget and on track to pour gold in the first half of 2024. We achieved commercial production at our new Santa Luz Mine in Brazil, commenced permitting for the Castle Mountain Phase 2 expansion, advanced the feasibility study and permitting for development of the Aurizona underground deposit, and demonstrated the potential for a significant expansion at Los Filos." 2022 highlights include: produced 532,319 ounces of gold, sold 532,127 ounces of gold; cash costs and all-in-sustaining costs will be provided with the Company's annual 2022 financial and operating results in late February.

07:05 EST XPO Logistics renews partnership with Truckers Against Trafficking - XPO has announced the renewal of its platinum partnership with Truckers Against Trafficking for 2023.

07:04 EST View Smart Windows selected for The Labs on 121 - Nightingale Properties and Real Estate Equities Corporation announced their new 10-story, 160,000-square-foot office development in uptown Manhattan's Harlem market, will feature Smart Windows from View. The Labs on 121, located at 2226 Third Avenue, marks the second partnership between View and Nightingale, following the 111 Wall Street office redevelopment with InterVest Capital Partners.

07:03 EST Kirkland's reports holiday comparable sales down 5.5% vs. previous year - Kirkland's announced its comparable sales results for holiday 2022, which include the first two months of the Company's Q4. Comparable sales for the fiscal Q4 through December 2022 decreased 5.5% compared to the same prior-year period. This includes flat comparable sales for November 2022 and an 11% decrease for December 2022, both compared to the same prior-year period. The decline in comparable sales for the month of December 2022 was larger than anticipated, so Kirkland's Home now expects ending the fiscal year with approximately $15M-$17M in net borrowings. The Company also now expects to end the fiscal year with inventory closer to the high end of the $70M-$80M range. "While sales trends began to improve in November, a continued volatile consumer environment in December impacted customer traffic following our Black Friday promotional events," said Steve "Woody" Woodward, president and CEO of Kirkland's Home. "We accelerated our promotional activity in December to generate sales momentum as we closed out the holiday season, but we were unable to overcome the impact from the decline in traffic and the effect on our merchandise mix of an extended period of significant inventory reduction. Based on the December sales results, we are adjusting our year-end balance sheet expectations accordingly."

07:02 EST Eargo announces 1-for-20 reverse stock split - Eargo announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock. The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on Wednesday, January 18 , under the existing trading symbol "EAR." Upon the effectiveness of the reverse stock split, every 20 shares of the Company's issued and outstanding common stock will be automatically reclassified into one share of issued and outstanding common stock. No fractional shares will be issued as a result of the reverse stock split. Instead, stockholders who otherwise would be entitled to receive fractional shares of common stock will be entitled to receive cash. The reverse stock split affects all stockholders uniformly and will not alter any stockholder's percentage interest in the Company's common stock, except for adjustments that may result from the treatment of fractional shares.

07:00 EST Eargo to complete a 1-for-20 reverse stock split - Eargo announced that its Board of Directors has approved a 1-for-20 reverse stock split of the Company's common stock. The Company's common stock is expected to begin trading on a split-adjusted basis when the markets open on Wednesday, January 18, 2023, under the existing trading symbol "EAR" and a new CUSIP number: 270087208. Upon the effectiveness of the reverse stock split, every 20 shares of the Company's issued and outstanding common stock will be automatically reclassified into one share of issued and outstanding common stock.

06:58 EST Talos Energy announces special meeting date for approval of EnVen acquisition - Talos Energy announced that the U.S. Securities and Exchange Commission has declared effective its Registration Statement on Form S-4 related to its previously announced acquisition of EnVen Energy Corporation (and that Talos has set a date of February 8, 2023 for the Special Meeting of its stockholders to vote and approve certain matters relating to such acquisition. Talos expects to close the transaction soon after the Special Meeting.

06:56 EST Tyson Foods to create 400 jobs at Caseyville Prepared Foods facility - Tyson Foods has expanded its workforce projections for its Caseyville Prepared Foods facility, creating approximately 400 new team member positions to meet the growing demand for Hillshire Farm and Jimmy Dean grab-n-go snacking and breakfast items. This boost in facility team members is a result of the $180M expansion currently in development. Seven state of the art production lines and 270,000 square feet will be added to the existing Caseyville facility to increase automated warehousing and robotics. The facility expansion officially broke ground in August 2022 and is expected to be complete in late 2024. The Caseyville facility plans to hire for positions across the maintenance, Food Safety Quality Assurance, warehousing, production, and management departments. About 250 of these team members are expected to start work across four new production lines by September 2023, while 150 are expected to begin work across three new production lines by the project's completion.

06:52 EST Eton Pharmaceuticals: FDA accepts NDA response for dehydrated alcohol injection - Eton Pharmaceuticals announced that the U.S. FDA has accepted for review the company's New Drug Application response for dehydrated alcohol injection for the proposed indication of methanol poisoning. The FDA has assigned a Prescription Drug User Fee Act target action date of June 27, 2023. Eton's application has previously been granted orphan drug designation for the indication of methanol poisoning and if approved, the company expects the FDA to grant the application seven years of orphan drug exclusivity. Based on IQVIA data, trailing twelve month sales for dehydrated alcohol injection were $74M.

06:47 EST Victoria's Secret approves $250M new share repurchase program - Victoria's Secret & Co. announced that its Board of Directors unanimously approved a new share repurchase program authorizing the repurchase of up to $250M of the Company's common stock. Shares repurchased under the January 2023 Share Repurchase Program will be made in the open market, subject to market conditions and other factors. The January 2023 Share Repurchase Program is eligible to begin upon exhaustion of the current $250M share repurchase program which is scheduled to be completed by the end of January 2023. Shares acquired through the January 2023 Share Repurchase Program will be available to meet obligations under equity compensation plans and for general corporate purposes. The January 2023 Share Repurchase Program will continue until exhausted, but no later than the end of FY23.

06:39 EST U.S. flights disrupted amid outage of FAA pilot advisory system - Air travel in the U.S. early Wednesday was disrupted by the failure of a key pilot notification system operated by the FAA. There was no estimate for the restoration of the Notice to Air Missions System and a hotline has been activated, the FAA said on its website. Publicly traded companies in the space include Alaska Air (ALK), American Airlines (AAL), Delta Air Lines (DAL), JetBlue (JBLU), Southwest (LUV), Spirit Airlines (SAVE) and United Airlines (UAL). Reference Link

06:33 EST Xenia Hotels upsizes, extends credit facility with $675M refinancing - Xenia Hotels & Resorts obtained a new $675M senior unsecured credit facility. The Credit Facility is comprised of a $450M revolving line of credit, a $125M term loan, and a $100M delayed draw term loan. The $450M Revolving Credit Facility matures in January 2027 and can be extended up to an additional year. The Revolving Credit Facility's interest rate is now based on a pricing grid with a range of 145 to 275 basis points over the applicable adjusted term SOFR rate as determined by the Company's leverage ratio up to a maximum of 7.25x, compared to the previous pricing grid which ranged from 150 to 275 basis points over LIBOR with a leverage ratio up to a maximum of 6.00x. The Company has full availability on its Revolving Credit Facility. The Initial Term Loan and Delayed Draw Term Loan each mature in March 2026, can be extended up to an additional year, and bear interest rates consistent with the pricing grid on the Revolving Credit Facility. The Company used the proceeds of the Initial Term Loan to pay off a $125M term loan that was due in September 2024. The Company intends to use the proceeds of the Delayed Draw Term Loan to pay off a $100M mortgage loan which is collateralized by the Renaissance Atlanta Waverly and due in August 2024. The Company's remaining 2024 debt maturities are limited to one $55M mortgage loan. The Credit Facility was arranged by JPMorgan Chase Bank, N.A., BofA Securities, Inc., KeyBanc Capital Markets, Inc., PNC Capital Markets LLC, and Regions Capital Markets, as Joint Lead Arrangers and Joint Bookrunners for the Revolving Credit Facility, the Initial Term Loan and the Delayed Draw Term Loan, and Fifth Third Bank, National Association served as a Joint Lead Arranger and Joint Bookrunner for the Initial Term Loan and the Delayed Draw Term Loan. JPMorgan Chase Bank, N.A. served as Administrative Agent, Bank of America, N.A., KeyBank National Association, PNC Bank, National Association and Regions Bank served as Co-Syndication Agents, Fifth Third Bank, National Association served as Documentation Agent, and Credit Agricole Corporate and Investment Bank served as Sustainability Structuring Agent. Other lenders included Goldman Sachs Bank USA, and Morgan Stanley Bank, N.A.

06:31 EST Ares Management raises $5B of infrastructure debt capital - Ares Management announced the final closing of its Infrastructure Debt Fund V, which is focused on making subordinated investments across the digital, utilities, renewables, energy and transportation sectors. IDF V held its final close on December 29, 2022, at approximately $5B, including General Partner commitments and related transaction vehicles.

06:27 EST Disneyland Resort announces new update, offer guests more value - Disney Resorts recently announced new updates to offer guests more "value and flexibility," the company said. Visitors can now switch between parks earlier with Park Hoppers ticket, beginning at 11 a.m. PT starting February 4. The company also expanded the number of days adult tickets are sold at $104, the park's lowest price, to a total of two months throughout 2023. Disney now provides complimentary Disney PhotoPass digital attraction photos. Finally, the company expanded the availability of its Magic Key passes. Reference Link

06:03 EST Schwazze announces executive leadership additions - Medicine Man Technologies operating as Schwazze announces changes to its executive leadership team in preparation for its growth initiatives in Colorado and New Mexico. Todd Williams, who has been acting as a Senior Advisor & Consultant for Mergers & Acquisitions and Real Estate, will become EVP, M&A and Real Estate. Williams has been a key member of the Schwazze Executive Leadership Team in an advisory capacity for the past three years and joins the Schwazze team as a full-time employee to continue his focus on M&A and real estate. Steve Pear is moving from head of the New Mexico division to become President, Wholesale Division, responsible for leading the Company's wholesale sales and marketing efforts. As a newly created role within the Company's Executive Leadership Team, Pear's focus will shift to optimizing our commercial footprint on a national scale while driving our core brands to the next level. He has been instrumental in leading the New Mexico team since the R.Greenleaf acquisition was completed in February of 2022. Replacing Pear in New Mexico is Ken Diehl as President, New Mexico Division. Most recently, Diehl was Chief Merchant for Leslie's Pool Supplies while also helping to project lead an IPO in specialty retail.

05:53 EST Elbit Systems awarded $70M contract to supply rockets to European country - Elbit Systems announced that it was awarded a contract in an amount of approximately $70M to supply rockets to the armed forces of a European country. The contract will be performed over a period of 3 years. Under the contract, Elbit Systems will supply 122mm extended-range rockets that are intended to significantly increase the performance and effectiveness of operations by allowing ground forces to concentrate fire at an increased range of up to 40 kilometers. The rocket offers simple autonomous operation in various weather conditions and can be ready to be launched in less than one minute.